» Articles » PMID: 16424049

Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-induced T Regulatory Cells and T-cell Anergy in Tumor-bearing Host

Overview
Journal Cancer Res
Specialty Oncology
Date 2006 Jan 21
PMID 16424049
Citations 715
Authors
Affiliations
Soon will be listed here.
Abstract

The accumulation of myeloid suppressor cells (MSCs) is associated with immune suppression in tumor-bearing mice and in cancer patients. The suppressive activity of MSC correlates with the expression of the myeloid markers Gr-1, CD115 (macrophage colony-stimulating factor receptor), and F4/80. Gr-1(+)CD115(+) MSCs, in addition to being able to suppress T-cell proliferation in vitro, can induce the development of Foxp3(+) T regulatory cells (Treg) in vivo, which are anergic and suppressive. Furthermore, the secretion of interleukin (IL)-10 and transforming growth factor-beta by Gr-1(+)CD115(+) MSCs was induced and enhanced, respectively, on IFN-gamma stimulation. The development of Treg requires antigen-associated activation of tumor-specific T cells, depends on the presence of IFN-gamma and IL-10, and is independent of the nitric oxide-mediated suppressive mechanism by MSC. Our data provide evidence that Gr-1(+)CD115(+) MSC can mediate the development of Treg in tumor-bearing mice and show a novel immune suppressive mechanism by which MSCs can suppress antitumor responses.

Citing Articles

Harnessing myeloid cells in cancer.

Park S, Pylaeva E, Bhuria V, Gambardella A, Schiavoni G, Mougiakakos D Mol Cancer. 2025; 24(1):69.

PMID: 40050933 PMC: 11887392. DOI: 10.1186/s12943-025-02249-2.


How modulation of the tumor microenvironment drives cancer immune escape dynamics.

Shrestha P, Ghoreyshi Z, George J Sci Rep. 2025; 15(1):7308.

PMID: 40025156 PMC: 11873109. DOI: 10.1038/s41598-025-91396-z.


Extracellular Vesicle-Based Strategies for Tumor Immunotherapy.

Jiramonai L, Liang X, Zhu M Pharmaceutics. 2025; 17(2).

PMID: 40006624 PMC: 11859549. DOI: 10.3390/pharmaceutics17020257.


Tumor-infiltrating myeloid cells; mechanisms, functional significance, and targeting in cancer therapy.

Toghraie F, Bayat M, Hosseini M, Ramezani A Cell Oncol (Dordr). 2025; .

PMID: 39998754 DOI: 10.1007/s13402-025-01051-y.


Modulation of tumor inflammatory signaling and drug sensitivity by CMTM4.

Xu Y, Kang K, Coakley B, Eisenstein S, Parveen A, Mai S EMBO J. 2025; .

PMID: 39948411 DOI: 10.1038/s44318-024-00330-y.